This lipid signature suggests that a more active ether-linked lipid synthesis pathway might be present in EGFR mutants and the plausible role of AGPS in the pathogenesis of EGFR mutation-driven NSCLC remains to be determined. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.